NeuroPace Inc false 0001528287 0001528287 2025-01-15 2025-01-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2025

 

 

NEUROPACE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40337   22-3550230

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

455 N. Bernardo Avenue

Mountain View, CA

   94043
(Address of principal executive offices)   (Zip Code)

(650) 237-2700

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   NPCE   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01 Regulation FD Disclosure

NeuroPace, Inc. (“NeuroPace”) is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at approximately 4:30 p.m. Pacific time (7:30 p.m. Eastern time), and the presentation will be available through a live audio webcast. The presentation materials will be available on the Events section of the NeuroPace investor site at https://investors.neuropace.com/news-and-events/events, along with instructions for accessing the webcast.

The foregoing information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    NeuroPace, Inc.
Dated: January 15, 2025     By:  

/s/ Rebecca Kuhn

      Rebecca Kuhn
      Chief Financial Officer and Vice President, Finance and Administration
v3.24.4
Document and Entity Information
Jan. 15, 2025
Cover [Abstract]  
Entity Registrant Name NeuroPace Inc
Amendment Flag false
Entity Central Index Key 0001528287
Document Type 8-K
Document Period End Date Jan. 15, 2025
Entity Incorporation State Country Code DE
Entity File Number 001-40337
Entity Tax Identification Number 22-3550230
Entity Address, Address Line One 455 N. Bernardo Avenue
Entity Address, City or Town Mountain View
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94043
City Area Code (650)
Local Phone Number 237-2700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol NPCE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Neuropace (NASDAQ:NPCE)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Neuropace.
Neuropace (NASDAQ:NPCE)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Neuropace.